stella
beta
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy — Stella
Recruiting
Back to HIV Associated Neurocognitive Disorder trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Yale School of Medicne, Neuro ID Research Program, New Haven, Connecticut
View full record on ClinicalTrials.gov